MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
OptimizeRx Corporation Book Value 2011-2025 | OPRX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value OptimizeRx Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 M | 126 M | 131 M | 50 M | 44.9 M | 18.5 M | 6.22 M | 7.81 M | 8.94 M | 4.61 M | 2.04 M | 1.5 M | 1.59 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 131 M | 1.5 M | 40.8 M |
Quarterly Book Value OptimizeRx Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 M | 119 M | 116 M | 117 M | 114 M | 121 M | 123 M | 127 M | 116 M | 116 M | 124 M | 126 M | 130 M | 141 M | 131 M | 131 M | 127 M | 125 M | 122 M | 50 M | 50 M | 50 M | 50 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 6.22 M | 9.76 M | 9.76 M | 9.76 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 7.03 M | 7.03 M | 7.03 M | 7.03 M | 3.95 M | 4.01 M | 4.01 M | 4.01 M | 2.18 M | 2.18 M | 2.18 M | 2.18 M | 1.59 M | 2.15 M | 1.03 M | 2.89 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 141 M | 1.03 M | 50.7 M |
Book Value of other stocks in the Health information services industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
3.68 B | - | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
187 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
1.53 B | - | - | $ 2.94 B | USA |
 |
Accolade
ACCD
|
391 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
7.25 B | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
715 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
26.4 M | - | - | $ 6.37 B | USA |
 |
Change Healthcare
CHNG
|
3.28 B | - | - | $ 9.03 B | USA |
 |
Evolent Health
EVH
|
859 M | $ 4.11 | -0.48 % | $ 385 M | USA |
 |
Health Catalyst
HCAT
|
365 M | $ 2.34 | -4.82 % | $ 141 M | USA |
 |
HealthStream
HSTM
|
511 M | $ 24.4 | 0.95 % | $ 741 M | USA |
 |
iCAD
ICAD
|
28.7 M | - | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
-7.01 M | - | - | $ 161 M | USA |
 |
HealthEquity
HQY
|
2.04 B | $ 96.06 | -0.75 % | $ 8.22 B | USA |
 |
American Well Corporation
AMWL
|
316 M | $ 4.68 | 1.3 % | $ 70.2 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.41 B | - | -10.39 % | $ 886 M | USA |
 |
Progyny
PGNY
|
422 M | $ 26.39 | -1.2 % | $ 2.26 B | USA |
 |
Premier
PINC
|
1.53 B | $ 28.26 | - | $ 2.33 B | USA |
 |
MTBC
MTBC
|
49.8 M | - | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
725 M | $ 2.72 | -3.72 % | $ 1.05 B | USA |
 |
Schrödinger
SDGR
|
421 M | $ 18.41 | 1.99 % | $ 1.34 B | USA |
 |
Omnicell
OMCL
|
1.24 B | $ 43.31 | -1.25 % | $ 1.99 B | USA |
 |
1Life Healthcare
ONEM
|
1.73 B | - | - | $ 3.37 B | USA |
 |
Phreesia
PHR
|
251 M | $ 16.68 | 2.71 % | $ 910 M | USA |
 |
So-Young International
SY
|
1.96 B | $ 2.92 | -5.66 % | $ 232 M |  China |
 |
Signify Health
SGFY
|
821 M | - | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
347 M | - | - | $ 3.81 B | USA |
 |
10x Genomics
TXG
|
741 M | $ 15.77 | 2.01 % | $ 1.85 B | USA |
 |
NantHealth
NH
|
-225 M | - | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
432 M | - | - | $ 1.6 B | USA |
 |
Veeva Systems
VEEV
|
4.64 B | $ 219.17 | -1.81 % | $ 35.2 B | USA |
 |
Zhongchao
ZCMD
|
24.2 M | $ 0.58 | -3.18 % | $ 3.02 M | China |
 |
Streamline Health Solutions
STRM
|
12.3 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
1.49 B | $ 7.36 | -2.65 % | $ 1.26 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-57 M | - | - | $ 255 M | USA |
 |
SCWorx Corp.
WORX
|
4.49 M | $ 0.21 | 5.86 % | $ 306 K | USA |